https://research.ouhsc.edu/news Parent Page: News id: 26727 Active Page: details id: 26917

News

OUHSC Research News – Monday, August 1, 2022


Published: Monday, August 1, 2022

OUHSC Research News – Monday, August 1, 2022

 

Notices and Reminders

SoonerTrack II Announcement

The Office of Research Administration (ORA) is pleased to announce that the SoonerTrack II system is now fully operational! All proposals must be routed through the new system for review, institutional approval, and submission to the sponsor.  The launch webpage for the system is https://fs.ou.edu. User guides and training materials are available at https://research.ouhsc.edu/research-administration/soonertrack-ii-support.  If you have any questions, please contact soonertrackhelpdesk@ouhsc.edu.

 

Important SoonerTrack Updates

**Please note that to be added to routing forms as Principal Investigator (PI) or personnel, you must log into https://fs.ou.edu as soon as possible. Other than logging in and out, you do not need to do anything else at this time. However, if you do not perform this initial login step, your department support will not be able to route forms for you nor will other researchers be able to add you to their projects in SoonerTrack.

If you are routing a proposal/agreement in SoonerTrack II and can’t find your department, please contact your business administrator. If you have any questions, please contact us at soonertrackhelpdesk@ouhsc.edu.

 

**As of Monday, July 18, 2022, all the tickets that were in active or pending ORA review statuses in old SoonerTrack are accessible in SoonerTrack II (new system).  While this will include most document types, Subawards and Independent Contract Agreements (ICAs) will be added separately and at a later date. If you are unable to find a ticket in the new system, please contact soonertrackhelpdesk@ouhsc.edu. 

Please be aware that as the conversion was a huge task, there are a few kinks we are working through.  As noted, if you experience issues, please contact your ORA Sponsored Programs Administrator or reach out to the Help Desk.

 

SoonerTrack II Training Opportunities

Have a question about the new SoonerTrack system? The Office of Research Administration (ORA) invites you to attend one of the SoonerTrack II Q&A sessions listed below, where you will have the opportunity to ask questions and receive answers from the subject matter experts. Registration is required. All sessions will be hosted virtually via Zoom. Questions may also be submitted ahead of time to soonertrackhelpdesk@ouhsc.edu.     

 

SoonerTrack II Live Q&A Sessions

  1. August 10, 2022 10:30 AM – 11:30 AM      Register here
  2. August 17, 2022 10:30 AM – 11:30 AM      Register here
  3. August 24, 2022 10:30 AM – 11:30 AM      Register here
  4. August 31, 2022 10:30 AM – 11:30 AM      Register here

 

Office of the Vice President for Research announces new Leadership for the Institutional Research Core Facility

James F. Papin, Ph.D. has been named as Director of the Institutional Research Core Facility, commonly referred to as the Laboratory for Molecular Biology and Cytometry Research (LMBCR).  Dr. Papin started in this new role as of July 25th and is contingent on final Board of Regents approval at their next meeting. Dr. Papin graduated from Oklahoma City University where he received a Bachelor of Science with honors in Biology before coming to the University of Oklahoma Health Sciences Center (OUHSC) where he earned his Ph.D. in the Department of Microbiology and Immunology. Following his doctoral studies on herpesviruses, Dr. Papin was a postdoctoral fellow at the University of California, Davis and at Boston University where he continued his research in the fields of virology and vaccine development.

In 2010, Dr. Papin returned to the OUHSC as a faculty member in the Department of Pathology. During his time at OUHSC, Dr. Papin has been promoted to Associate Professor and he has served the campus in several leadership roles, including as the Director of the High Containment Biosafety Level 3 Laboratory and as the Institutional Biosafety Officer. He also has served on several important institution-wide oversight committees, including the Institutional Biosafety Committee and the Institutional Animal Care and Use Committee.

Along with his new duties as Director of the Institutional Research Core Facility, Dr. Papin will oversee the Technical Service Unit in the Division of Comparative Medicine as Associate Director.  He also continues to pursue his highly productive independent research program focused on virology and vaccine development.

Some of his initial goals as Director of the Institutional Research Core Facility will be to enhance customer service and oversight of all research units within the Core Facility.  He will also work closely with faculty utilizing Core services and ensure the Core capabilities and equipment resources can be easily accessed by all faculty and trainees and that these resources are widely communicated throughout the research community. 

We look forward to his leadership in this position where he will support the advancement of outstanding research at OUHSC and help our faculty achieve nationally recognized research outcomes using cutting edge research technology.

 

The Office of Vice President for Research (OVPR) and the Office of Research Administration (ORA) at the OU Health Sciences Center Announcing the Launch of the Newly Redesigned Website

We are excited to announce the launch of our newly redesigned website. The new design allows for streamlined menus and clear navigation, and offers quick and easy access to essential information for our faculty and staff. Explore the website at https://research.ouhsc.edu. We welcome your feedback. Please send any questions or comments to oradmin@ouhsc.edu.

 

NIH Reminder: All NIH-funded clinical trials are expected to register and submit results information to Clinicaltrials.gov, as per the “NIH Policy on Dissemination of NIH-Funded Clinical Trial Information for competing applications and contract proposals. The requirements for registration and results reporting are:

  • Recipients must ensure that their NIH-funded clinical trials are registered at ClinicalTrials.gov for public posting no later than 21 days after enrollment of the 1st participant.
  • Results information must be submitted to ClinicalTrials.gov no later than one year after primary completion date (with limited exceptions).

If your RPPR has associated clinical trials that do not comply with these requirements, you may receive errors that prevent the RPPR from being submitted.

 

NIH Notice: eRA Retirement of All Application Form Versions Prior to FORMS-E (NOT-OD-22-182) 

The purpose of this notice is to inform the applicant community that eRA Application Submission System and Interface for Submission Tracking (ASSIST) will no longer support all application form versions prior to FORMS-E by the end of August 2022.  https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-182.html

 

Workshops and Seminars

Webinar I: Understanding the New NIH Data Management and Sharing Policy 

Date: Thursday, August 11, 1/24/22, 12:30 - 2:30 PM (Central)

Description: The NIH Office of Science Policy (OSP) and the Office of Extramural Research (OER) invite you to join them for an engaging and interactive webinar focused on the new DMS policy which goes into effect on January 25, 2023. In this webinar, you will learn about DMS policy expectations, the applicability of the policy, how to prepare a Data Management and Sharing Plan, and considerations for sharing data responsibly. Don't miss this valuable opportunity to hear from policy experts and get your questions answered. Registration: https://vfairs.zoom.us/webinar/register/WN_CtZuYKxtTeioXptg43JDgg

 

Webinar II: Diving Deeper into the New NIH Data Management and Sharing Policy 

Date: Thursday, September 22, 2022 / 12:30 - 2:30 PM (Central)

Description: The NIH Office of Science Policy (OSP) and the Office of Extramural Research (OER) invite you to join them for an engaging and interactive webinar focused on the new DMS policy which goes into effect on January 25, 2023. In this second webinar of the series, we will expand upon the information presented in the first webinar and dive deeper into topics including privacy protections for data from human participants and justifiable limitations on sharing data. Don't miss this valuable opportunity to hear policy experts provide the latest information and to get your questions answered.

Registration: https://vfairs.zoom.us/webinar/register/WN_3y9GFMc2SsWpv2GhIzOGsg

 

SAVE THE DATE! 2022 END2CANCER
OU Health Stephenson Cancer Center is proud to host the 2022 END2CANCER: Emerging Nanotechnology and Drug Delivery Applications for Cancer conference from December 1-2, 2022 in Oklahoma City, Oklahoma, USA. The END2CANCER conference will start the morning of December 1, 2022 and conclude in the afternoon of December 2, 2022. The conference will bridge laboratory research conducted in the areas of nanotechnology and drug delivery to clinical application for the detection, diagnosis, imaging and treatment of cancer. The conference will host keynote, plenary and invited lectures by eminent scientists who will discuss new and emerging concepts, technologies and challenges in translating nanomedicine from bench-to-bedside.
Topics to be discussed in the planned thematic sessions include Gene and Drug Delivery, Immuno-Oncology, Drug Discovery and New Drugs on the Horizon for Clinical Translation, Extracellular Vesicles, Combinatorial Therapeutics, and more to come. 
The multi-disciplinary two-day conference will bring together physicians, basic scientists, engineers, physicists, chemists, post-doctoral fellows, high-school and college students, patient advocates, business professionals, educators and technology transfer specialists. Students and fellows will have an opportunity to present their work and compete for cash awards. We will again be hosting a special session titled "Art of Science in Light of Nanomedicine" will allow participants to display their best research as a photo with a caption and compete for a cash prize.

 

Melanoma Research Alliance: Webinar Q&A: Securing CDMRP Funding - Tips from MRA

Join the Melanoma Research Alliance on Thursday, August 4 from 1 - 1:30 PM to learn about - and get tips for securing funding from - the U.S. Department of Defense Melanoma Research Program.

This interactive discussion will feature:

  1. Marc Hurlbert, PhD, MRA Chief Executive Officer, who will share an overview of the CDMRP Melanoma Research Program and its FY22 funding opportunities;
  2. Andrew Aplin, PhD (Thomas Jefferson University) who will share insight and experiences as a recipient of multiple grants from the CDMRP; &
  3. Ed Ackerley, Pre Award Program Manager (University of Notre Dame) who will share tips and best practices to support grants administration offices.

Register here.

 

OUHSC Funding Opportunities

Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).  

  • A US materials science company is seeking materials, processes and expertise for immobilization of enzymes used for chemical catalysis.  Methods to manipulate material properties, reactor configurations and reaction process conditions to increase activity, selectivity, durability and/or recyclability are of particular interest. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 08/20).
  • Bayer Consumer Health is seeking biome-targeted solutions suitable for non-pharmaceutical oral and/or topical consumer use in the areas of upper respiratory illness, gut microbiome, digestive health, and skin.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 08/20).
  • FMC is looking for biodegradable hydrolytically stable technologies that can encapsulate active ingredients for use in crop protection.  Encapsulation technologies that can reduce volatility of active ingredients are preferred.  Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 08/20).
  • ELI Lilly is seeking druggable targets for weight loss, in particular approaches focused on appetite modulation, energy expenditure and mechanisms synergistic with GLP-1.  All mechanisms and modalities are of interest as is drug repurposing.  Out of scope includes plant/food based approaches and probiotics/microbiome targeting (unless weight loss is robust). Submission entails a 1-pg non-confidential summary of technology with optional supplemental information.  (deadline 08/25).

 

 NIH Notices 

NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted).  The letters of intent will be reviewed and a single application will be chosen for submission from the University.

 

NIH Funding Opportunities

 

Other Funding Opportunities

The International Center for Responsible Gaming - ICRG Center of Excellence for Gambling Research

Description: The purpose of this funding opportunity is to advance development, implementation and validation of interventions to minimize gambling-related harm through responsible gambling programs. The ICRG is especially interested in understanding and addressing the low usage of responsible gambling tools. Applicants may request up to $402,500 for a three-year grant.

Application Deadline: October 1, 2022

Link to Full Announcement: https://www.icrg.org/research-center/apply-icrg-funding

 

The International Center for Responsible Gaming - Large Grant on Gambling among Emerging Adults

Description: The International Center for Responsible Gaming (ICRG) invites investigators to apply for research grants to study gambling and gambling problems among emerging adults in the US. Applicants may request up to $172,500 for a two-year grant.

Application Deadline: October 1, 2022

Link to Full Announcement: https://www.icrg.org/research-center/apply-icrg-funding

 

The Melanoma Research Alliance (MRA) - Patient-Centric Clinical Trial Team Science Awards

Description: The Melanoma Research Alliance (MRA) is pleased to announce a Special Opportunity RFP for Team Science Awards focused on patient-centric clinical trials, jointly funded by The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and MRA. MRA and RTFCCR will jointly support two team awards (each up to $1.5 million) for clinical trials with the potential to provide significant impact to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination.

Letters of Intent Due: October 5, 2022

Invited Full Proposals Due: January 18, 2023

Link to Full Announcement: CureMelanoma.org/RFP

 

Oklahoma Center for Adult Stem Cell Research (OCASCR)

Description: The overall goal of OCASCR is to help adult stem cell and regenerative medicine research thrive in Oklahoma and to serve as a trusted resource for public information on these topics. Grants are accepted for research, equipment, and travel/education, and other areas.

Application Deadline: September 20, 2022

Link to Full Announcement: http://www.ocascr.org/grants/

 

The International Center for Responsible Gaming - Small Grants for Research on Lottery Gambling

Description: The International Center for Responsible Gaming and the Hoosier Lottery are collaborating on a special initiative to encourage research on responsible gambling as it relates to lottery gambling. Research projects may include but are not limited to: 

  • Stand-alone research projects or a pilot project; 
  • Preliminary research in preparation for a large research project, such as a comprehensive literature review, or instrument development and testing; and 
  • Research tasks subsequent to a full research project, such as follow-up testing. 

Applicants may request up to $25,000 in direct costs and $5,000 in Facilities and Administration costs

Application Deadline: September 1, 2022

Link to Full Announcement: https://www.icrg.org/research-center/apply-icrg-funding

 

The Oklahoma Center for the Advancement of Science and Technology (OCAST)  Notice of Funding Opportunity Announcements. OCAST has published a list of Funding Opportunity Announcements for FY 2022. The guidelines for 2022 have not been released yet. Next application submission period opens on August 15, 2022 and closes September 26, 2022. More information about the funding opportunity announcements and additional resources are available here: https://oklahoma.gov/ocast/ogx-overview/funding-opportunities.html.